Daily Stock Analysis, MACK, Merrimack Pharmaceuticals Inc, priceseries

Merrimack Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
5.90
Close
5.85
High
6.10
Low
5.75
Previous Close
5.99
Daily Price Gain
-0.14
YTD High
7.12
YTD High Date
Feb 22, 2022
YTD Low
3.66
YTD Low Date
Jan 5, 2022
YTD Price Change
1.88
YTD Gain
47.36%
52 Week High
7.97
52 Week High Date
Apr 26, 2021
52 Week Low
3.66
52 Week Low Date
Jan 5, 2022
52 Week Price Change
-0.73
52 Week Gain
-11.09%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
May 9. 2017
13.09
May 17. 2017
13.84
6 Trading Days
5.75%
Link
LONG
Jan 2. 2019
2.84
Mar 1. 2019
4.16
40 Trading Days
46.71%
Link
LONG
Mar 11. 2019
4.45
Mar 22. 2019
4.73
9 Trading Days
6.48%
Link
LONG
Jul 25. 2019
4.06
Aug 14. 2019
4.59
14 Trading Days
13.04%
Link
LONG
Sep 10. 2019
4.92
Sep 12. 2019
5.21
2 Trading Days
5.97%
Link
LONG
Mar 30. 2020
2.14
Apr 20. 2020
3.31
14 Trading Days
54.61%
Link
LONG
Nov 27. 2020
3.83
Dec 16. 2020
7.02
13 Trading Days
83.19%
Link
LONG
Feb 17. 2021
8.27
Feb 18. 2021
8.81
1 Trading Days
6.53%
Link
LONG
Jan 11. 2022
3.97
Jan 24. 2022
4.34
8 Trading Days
9.37%
Link
LONG
Feb 18. 2022
6.20
Feb 23. 2022
6.60
2 Trading Days
6.45%
Link
Company Information
Stock Symbol
MACK
Exchange
NasdaqGM
Company URL
http://www.merrimackpharma.com
Company Phone
617-441-1000
CEO
Richard Peters
Headquarters
Massachusetts
Business Address
ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE, MA 02139
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001274792
About

Merrimack Pharmaceuticals, Inc. engages in discovering, developing and preparing to commercialize innovative medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its offers its first commercial product, Onivyde, which is a novel encapsulation of the marketed chemotherapy drug irinotecan in liposomal formulation. The company was founded by Anthony J. Sinskey, Gavin MacBeath and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA.

Description

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. It offers ONIVYDE that is used for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. The company's therapeutic oncology candidates in clinical development include MM-398, which is in Phase II clinical trial for treating patients with previously untreated, metastatic pancreatic adenocarcinoma; Phase I clinical trial for the treatment of glioma, pediatric solid tumors, and gastrointestinal tumors; and Phase I clinical trial for treating metastatic breast cancer. Its therapeutic oncology candidates also include MM-302 for treating patients with ErbB2 (HER2) positive, locally advanced or metastatic breast cancer; and MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer. In addition, the company's therapeutic oncology candidates consist of MM-141 that is in Phase II clinical trial for treating previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1; MM-151 that has completed a Phase I clinical trial for treating solid tumors; and MM-310 for treating solid tumors. Further, it is developing preclinical product candidates for solid tumor indications. The company has license and collaboration agreements with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA; development, license, and supply agreement with Watson Laboratories, Inc.; sublicense and collaboration agreement with PharmaEngine, Inc.; collaboration agreements with Dyax Corp. and Adimab LLC,; and license agreement with University of California. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.